Haemonetics traded at $61.19 this Friday February 20th, increasing $0.52 or 0.86 percent since the previous trading session. Looking back, over the last four weeks, Haemonetics gained 12.72 percent. Over the last 12 months, its price fell by 2.90 percent. Looking ahead, we forecast Haemonetics to be priced at 59.29 by the end of this quarter and at 53.95 in one year, according to Trading Economics global macro models projections and analysts expectations.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. It markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.